The FDA has cleared Kapidex, a capsule to treat gastroesophageal reflux disease that releases the drug in two stages, to spread out the dose evenly. An eight-week trial found a 60-milligram dosage of Kapidex resulted in comparable overall healing rates compared to a 30-milligram dosage of Prevacid.

Related Summaries